NASDAQ:PDEXPro-Dex Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pro-Dex Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $20.75 +0.51 (+2.52 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$20.75Now: $20.75▼$20.7550-Day Range$17.00MA: $18.75▼$20.8052-Week Range$11.40Now: $20.75▼$23.90Volume700 shsAverage Volume8,736 shsMarket Capitalization$80.30 millionP/E Ratio19.04Dividend YieldN/ABeta1.18 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Pro-Dex. Previous Next 2.3 Community Rank Outperform VotesPro-Dex has received 87 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPro-Dex has received 106 “underperform” votes. (Add your “underperform” vote.)Community SentimentPro-Dex has received 54.92% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote “Outperform” if you believe PDEX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPro-Dex does not currently pay a dividend.Dividend GrowthPro-Dex does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pro-Dex insiders have not sold or bought any company stock.Percentage Held by Insiders38.60% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.60% of the stock of Pro-Dex is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pro-Dex is 19.04, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.26.Price to Earnings Ratio vs. SectorThe P/E ratio of Pro-Dex is 19.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.03.Price to Book Value per Share RatioPro-Dex has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.79 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PDEX Previous Symbol CUSIPN/A CIK788920 Webwww.pro-dex.com Phone949-769-3200Debt Debt-to-Equity Ratio0.20 Current Ratio4.64 Quick Ratio2.69Price-To-Earnings Trailing P/E Ratio19.04 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$27.17 million Price / Sales2.96 Cash Flow$1.12 per share Price / Cash Flow18.58 Book Value$4.14 per share Price / Book5.01Profitability EPS (Most Recent Fiscal Year)N/A Net Income$4.15 million Net Margins14.50% Return on Equity25.64% Return on Assets16.13%Miscellaneous Employees80 Outstanding Shares3,870,000Market Cap$80.30 million Next Earnings Date9/3/2020 (Estimated) OptionableNot Optionable $20.75 +0.51 (+2.52 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PDEX News and Ratings via Email Sign-up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter. Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions How has Pro-Dex's stock been impacted by COVID-19 (Coronavirus)? Pro-Dex's stock was trading at $18.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PDEX stock has increased by 13.8% and is now trading at $20.75. View which stocks have been most impacted by Coronavirus. When is Pro-Dex's next earnings date? Pro-Dex is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020. View our earnings forecast for Pro-Dex. How were Pro-Dex's earnings last quarter? Pro-Dex Inc (NASDAQ:PDEX) released its earnings results on Thursday, May, 7th. The medical instruments supplier reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.08. The medical instruments supplier had revenue of $8.51 million for the quarter. Pro-Dex had a net margin of 14.50% and a return on equity of 25.64%. View Pro-Dex's earnings history. Has Pro-Dex been receiving favorable news coverage? Media stories about PDEX stock have trended extremely negative on Sunday, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pro-Dex earned a daily sentiment score of -4.8 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Pro-Dex. Who are some of Pro-Dex's key competitors? Some companies that are related to Pro-Dex include RenovaCare (RCAR), Utah Medical Products (UTMD), Iradimed (IRMD), Repare Therapeutics (PYPD), iCAD (ICAD), Accuray (ARAY), Pulse Biosciences (PLSE), Westaim (WEDXF), T2 Biosystems (TTOO), Liquidia Technologies (LQDA), Lyra Therapeutics (LYRA), Apyx Medical (APYX), TELA Bio (TELA), Restoration Robotics (HAIR) and Soliton (SOLY). View all competitors. What other stocks do shareholders of Pro-Dex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), AT&T (T), Bank of America (BAC), Enterprise Products Partners (EPD), Micron Technology (MU), NovaBay Pharmaceuticals (NBY), NVIDIA (NVDA), AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR) and Alibaba Group (BABA). Who are Pro-Dex's key executives? Pro-Dex's management team includes the following people: Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 58)Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 49) What is Pro-Dex's stock symbol? Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX." Who are Pro-Dex's major shareholders? Pro-Dex's stock is owned by many different institutional and retail investors. Top institutional shareholders include LSV Asset Management (1.35%). Company insiders that own Pro-Dex stock include Alisha Charlton, David Hovda, Kirk Richard Lee Van Jr, Nicholas John Swenson and Raymond E Cabillot. View institutional ownership trends for Pro-Dex. Which major investors are buying Pro-Dex stock? PDEX stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management. View insider buying and selling activity for Pro-Dex. How do I buy shares of Pro-Dex? Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Pro-Dex's stock price today? One share of PDEX stock can currently be purchased for approximately $20.75. How big of a company is Pro-Dex? Pro-Dex has a market capitalization of $80.30 million and generates $27.17 million in revenue each year. Pro-Dex employs 80 workers across the globe. What is Pro-Dex's official website? The official website for Pro-Dex is www.pro-dex.com. How can I contact Pro-Dex? Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected] This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
